Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Madrigal Pharmaceuticals
Marketing
Amid a new MASH market, ‘tremendous change’ is on the horizon
With the FDA approval of the first specific drug for MASH in March, Madrigal’s Rezdiffra is a pioneer in a market that is set for rapid change.
Ben Adams
Nov 5, 2024 10:02am
Novo Nordisk's semaglutide delivers in phase 3 MASH study
Nov 1, 2024 10:38am
Madrigal's MASH drug Rezdiffra 'blew away' expectations in Q3
Oct 31, 2024 3:24pm
Madrigal maps out 'Way Forward' for MASH patients with Rezdiffra
Sep 6, 2024 6:30am
Madrigal tipped to target scientific events to boost MASH growth
Aug 12, 2024 8:15am
Sales strong for Madrigal's Rezdiffra, but shares down 13%
Aug 7, 2024 2:56pm
